Monthly data to track physician preference for invasive and non-invasive colorectal cancer screening tests
September 22, 2015 (New York) — Guidepoint, a leading expert network firm and provider of TRACKER data, today announced the launch of the Colorectal Cancer Screening (CRC) TRACKER, a subscription-based data service that delivers monthly data on volume, market share, adoption rates, and more for various colorectal cancer screening tests.
The Colorectal Cancer Screening TRACKER offers critical insights on both invasive and non-invasive screening methods, including colonoscopy, sigmoidoscopy, CT colonoscopy, fecal immunochemical test (FIT), fecal occult blood test (FOBT), and others. TRACKER data includes number of tests ordered, number of patients over the age of 50, patient test compliance rates, and number of sites.
The CRC Screening TRACKER will also capture data for the newly approved screening test manufactured by Exact Sciences and co-marketed by Ironwood Pharmaceuticals and will be well-positioned to capture data for colorectal cancer screening tests as they are approved and launched in the future.
Kenneth Wahl, Vice President, Business Development for Guidepoint TRACKER, said: “Invasive tests, particularly colonoscopy, have been the gold standard for colorectal cancer screening, but for a variety of reasons physicians turn to non-invasive screening tests as the primary screening method. By applying its TRACKER methodology and expertise, Guidepoint is in a unique position to capture and report to clients uptake, market share, number of sites, and patient adherence rate data.”
Data for the CRC Screening TRACKER is collected from an anonymous, same-site panel of physicians at family and internal medicine practices, composed of single physicians, private groups, community hospitals, and academic hospitals. Each month the panel will also provide insurance coverage data for newer tests as well as periodic timely panel feedback on awareness, perception, and other qualitative and quantitative data.
The Colorectal Cancer Screening TRACKER is part of the Guidepoint TRACKER suite of data products that tracks trends in the medical device and therapeutic sectors. Data is available to subscribers through the Guidepoint TRACKER website.
For more information, visit www.guidepoint.com/tracker.
About Guidepoint TRACKER
Since 2006, Guidepoint TRACKER has equipped institutional investors and manufacturers with monthly volume, market share, and other commercial insights for medical device and biopharmaceutical utilization, as reported by representative, anonymous, same-site panels.
Today, Guidepoint offers 29 TRACKER data and market models available exclusively to Guidepoint clients via a web-based platform.
Guidepoint, a leading expert network firm, connects business decision-makers with experts around the world. Since 2003, Guidepoint has provided its clients with practical insights, setting up more than 500,000 interactions. Its slate of services, including phone consultations and meetings with Advisors, custom surveys, and proprietary data products, help professionals gain comprehensive understanding of a topic before making strategic or investment decisions. Guidepoint’s multinational client list includes seven of the top 10 consulting firms, seven of the top 10 hedge funds, and some of the largest private equity firms and Fortune-ranked companies. Guidepoint’s industry-leading compliance platform—overseen by Guidepoint’s General Counsel, a former SEC enforcement attorney—supports appropriate client-to-Advisor interactions through the application of Guidepoint’s own policies and procedures as well as custom, client-specific controls the company implements at clients’ requests. For more information, visit www.guidepoint.com.